Komori
Share Issuance and Disposal4564OncoTherapy Science,Inc.Pharmaceuticals

Notice Concerning the Large-Scale Exercise of the 38th Series Stock Acquisition Rights through a Third-Party Allotment (with Exercise Price Adjustment Clause)

From 1 June to 9 June 2026, 96,000 of the 38th Stock Acquisition Rights were exercised, and 9.6 million new shares were delivered. As of the end of the period, the unexercised balance was 150,000 rights (15 million shares).

Worth reading
30Immaterial
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
9600000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Substantial exercise of the 38th Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause)

発行・処分する株式数9,600,000Shares

Shares delivered since the beginning of the month: 9,600,000 new shares (transferred treasury shares: none)

発行済株式総数

Exercise ratio since the beginning of the month: 12.06% of the total number issued

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
¥19.6 and ¥17.7. The rights include an exercise price adjustment clause, but the adjustment floor is Not disclosed
Number of Stock Acquisition Rights
Total number issued: 796,000 rights (calculated from 96,000 rights representing 12.06% of the total number issued); unexercised at the end of the preceding month: 246,000 rights; currently unexercised: 150,000 rights
Basis for determining the amount to be paid
Exercise price: ¥19.6 from 1 June to 5 June 2026, and ¥17.7 on 8 and 9 June 2026. The basis for determination and discount rate are Not disclosed
Most recent equity financing
Announced on 21 November 2025: issuance of new shares and the 38th Stock Acquisition Rights through a third-party allotment (with an exercise price adjustment clause) (detailed amount: Not disclosed)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalSubstantial exercise of the 38th Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause)
Number of shares to be issued or disposed ofShares delivered since the beginning of the month: 9,600,000 new shares (transferred treasury shares: none)
Dilution RateExercise ratio since the beginning of the month: 12.06% of the total number issued
Total number of issued shares398,643,700 shares (as of the end of the month preceding the target month) → Not disclosed
Basis for determining the amount to be paidExercise price: ¥19.6 from 1 June to 5 June 2026, and ¥17.7 on 8 and 9 June 2026. The basis for determination and discount rate are Not disclosed
Exercise price¥19.6 and ¥17.7. The rights include an exercise price adjustment clause, but the adjustment floor is Not disclosed
Number of Stock Acquisition RightsTotal number issued: 796,000 rights (calculated from 96,000 rights representing 12.06% of the total number issued); unexercised at the end of the preceding month: 246,000 rights; currently unexercised: 150,000 rights
Most recent equity financingAnnounced on 21 November 2025: issuance of new shares and the 38th Stock Acquisition Rights through a third-party allotment (with an exercise price adjustment clause) (detailed amount: Not disclosed)
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the status of the bulk exercise. No other reason is disclosed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Large-Scale Exercise of the 38th Series Stock Acquisition Rights through a Third-Party Allotment (with Exercise Price Adjustment Clause) | OncoTherapy Science,Inc. (4564) timely disclosure | Komori